Beam Therapeutics ( (BEAM) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beam Therapeutics shares are sliding as traders refocus on safety worries in updated Phase 1/2 results for its AATD candidate BEAM-302, where a small multi-dose group showed worrying spikes in liver enzymes after repeat dosing. The selloff reflects a classic sell-the-news reaction and profit-taking after recent gains, with broader biotech weakness and jittery markets adding extra pressure despite a fresh Citi price-target hike.
Investors had initially cheered BEAM-302’s strong efficacy, but the safety signals and long road to potential approval are now weighing more heavily on sentiment. With the market repricing regulatory and execution risks, the bullish call from Citigroup is failing to stabilize the stock, leaving Beam Therapeutics among today’s notable decliners.
More about Beam Therapeutics
YTD Price Performance: -14.79%
Average Trading Volume: 1,933,074
Technical Sentiment Signal: Strong Sell
Current Market Cap: $2.41B
For further insights into BEAM stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.